Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
RASA1 maintains the lymphatic vasculature in a quiescent functional state in mice
Philip E. Lapinski, … , Eva Sevick-Muraca, Philip D. King
Philip E. Lapinski, … , Eva Sevick-Muraca, Philip D. King
Published January 9, 2012
Citation Information: J Clin Invest. 2012;122(2):733-747. https://doi.org/10.1172/JCI46116.
View: Text | PDF
Research Article Angiogenesis

RASA1 maintains the lymphatic vasculature in a quiescent functional state in mice

  • Text
  • PDF
Abstract

RASA1 (also known as p120 RasGAP) is a Ras GTPase–activating protein that functions as a regulator of blood vessel growth in adult mice and humans. In humans, RASA1 mutations cause capillary malformation–arteriovenous malformation (CM-AVM); whether it also functions as a regulator of the lymphatic vasculature is unknown. We investigated this issue using mice in which Rasa1 could be inducibly deleted by administration of tamoxifen. Systemic loss of RASA1 resulted in a lymphatic vessel disorder characterized by extensive lymphatic vessel hyperplasia and leakage and early lethality caused by chylothorax (lymphatic fluid accumulation in the pleural cavity). Lymphatic vessel hyperplasia was a consequence of increased proliferation of lymphatic endothelial cells (LECs) and was also observed in mice in which induced deletion of Rasa1 was restricted to LECs. RASA1-deficient LECs showed evidence of constitutive activation of Ras in situ. Furthermore, in isolated RASA1-deficient LECs, activation of the Ras signaling pathway was prolonged and cellular proliferation was enhanced after ligand binding to different growth factor receptors, including VEGFR-3. Blockade of VEGFR-3 was sufficient to inhibit the development of lymphatic vessel hyperplasia after loss of RASA1 in vivo. These findings reveal a role for RASA1 as a physiological negative regulator of LEC growth that maintains the lymphatic vasculature in a quiescent functional state through its ability to inhibit Ras signal transduction initiated through LEC-expressed growth factor receptors such as VEGFR-3.

Authors

Philip E. Lapinski, Sunkuk Kwon, Beth A. Lubeck, John E. Wilkinson, R. Sathish Srinivasan, Eva Sevick-Muraca, Philip D. King

×

Figure 8

Lymphatic vessel growth in vivo in induced RASA1-deficient mice.

Options: View larger image (or click on image) Download as PowerPoint
Lymphatic vessel growth in vivo in induced RASA1-deficient mice.
(A) Who...
(A) Whole mount diaphragms from Rasa1fl/flProx1ert2cre, Rasa1fl/flUbert2cre, and Rasa1fl/fl mice injected with TM 3 months prior were stained with anti–LYVE-1 or anti–VE-cadherin antibodies (red) and anti-Prox1 antibodies (green). (B) Lymphatic vessel diameter in diaphragms of mice in A. Data (mean + 1 SEM) are derived from 6 randomly selected fields from 3 mice per genotype. ***P < 0.001. (C) Rasa1fl/flUbert2cre and Rasa1fl/fl mice were administered TM at 2 months of age, then BrdU 8 and 10 days later. 2 hours after the last BrdU dose, whole mount diaphragms were stained with anti–LYVE-1 and anti-BrdU antibodies. Note the numerous lymphatic sprouts (arrowheads) and BrdU+ nuclei (arrows) in Rasa1fl/flUbert2cre mice. Images are representative of 3 mice per genotype. The boxed region is shown enlarged 3-fold. (D) Rasa1fl/flUbert2cre and Rasa1fl/fl mice were administered TM at 2 months, then BrdU 3 and 5 days later. 2 hours after the last BrdU injection, whole lung cell suspensions were analyzed by flow cytometry. Shown are representative 2-color plots of podoplanin versus CD31 staining on gated CD45– cells (blue gates denote LEC and BEC populations) and BrdU staining within LECs and BECs. Numbers indicate percent representation among total live cells in each plot. Similar results were obtained in 2 repeat experiments. Original magnification, ×100 (A, top); ×400 (A, bottom, and C).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts